Valneva SE
Research Valneva SE (VALN) on Bullrun: market cap USD 562.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVALN
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 562.30M
- Financial periodQ2 2026
- RevenueEUR 34.94M
- Net income-EUR 31.20M
- Free cash flow-EUR 13.77M
- Gross margin4.6%
Valuation Snapshot
latest market cap is USD 562.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 174.66M | -EUR 115.19M | -EUR 57.38M | 38.7% | -1.36 | EUR 109.65M | EUR 207.25M | EUR 106.17M |
| FY2024 | EUR 169.58M | -EUR 12.25M | -EUR 83.66M | 41.9% | -0.16 | EUR 168.27M | EUR 216.31M | EUR 181.25M |
| FY2023 | EUR 153.71M | -EUR 101.43M | -EUR 217.06M | 34.4% | -1.46 | EUR 126.08M | EUR 208.82M | EUR 128.25M |
| FY2022 | EUR 361.30M | -EUR 143.28M | -EUR 274.67M | 10.2% | -2.48 | EUR 286.53M | EUR 152.38M | EUR 219.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 562.30M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 749.98M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 354.84M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 719.61M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 879.81M | 7.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.92B | n/a | n/a | n/a |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Valneva SE's market cap?
Valneva SE's market capitalization is USD 562.30M.
What does Valneva SE do?
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.